Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series

Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series

IntroductionAnti-CD20 monoclonal antibody (mAb) therapies used to treat multiple sclerosis (MS) differ in their molecular structures, epitope recognition, and mechanisms of CD20-positive (CD20+) cell lysis, which may impact clinical efficacy and tolerability and support within-class switching for pa...

Full description

Saved in:

Bibliographic Details
Main Authors:	Regina Berkovich, Jonathan Calkwood, Heidi Crayton, April Erwin, Simon Faissner, Ralf Gold, Joshua Katz, Mark Leekoff
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-04-01
Series:	Frontiers in Immunology
Subjects:	anti-CD20 B-cell depletion disability magnetic resonance imaging multiple sclerosis ocrelizumab
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1527102/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Corrigendum: Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series
by: Regina Berkovich, et al.
Published: (2025-06-01)

Correction: B cell-extrinsic and intrinsic factors linked to early immune repletion after anti-CD20 therapy in patients with multiple sclerosis of African ancestry
by: Gregg J. Silverman, et al.
Published: (2025-07-01)

B cell-extrinsic and intrinsic factors linked to early immune repletion after anti-CD20 therapy in patients with multiple sclerosis of African ancestry
by: Gregg J. Silverman, et al.
Published: (2025-06-01)

Tryptophan pathway profiling in multiple sclerosis patients treated with ocrelizumab
by: Carolina Ricci, et al.
Published: (2025-06-01)

Effects of Anti-CD20 Antibody Therapy on Immune Cell Dynamics in Relapsing-Remitting Multiple Sclerosis
by: Alice G. Willison, et al.
Published: (2025-04-01)

CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany
by: Mathias Buttmann, et al.
Published: (2025-05-01)

Vaccine-Induced Humoral and Cellular Response to SARS-CoV-2 in Multiple Sclerosis Patients on Ocrelizumab
by: Jelena Drulovic, et al.
Published: (2025-04-01)

Comparative effectiveness, safety and persistence of ocrelizumab versus natalizumab in multiple sclerosis: A real-world, multi-center, propensity score-matched study
by: Elena Barbuti, et al.
Published: (2025-03-01)

Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review
by: D. L. Klabukova, et al.
Published: (2018-11-01)

Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis
by: A. N. Boyko, et al.
Published: (2019-11-01)

Kappa free light chain concentration in serum is reduced after CD20-depletion with ocrelizumab
by: Franz Felix Konen, et al.
Published: (2025-08-01)

Real-World Persistence with Ocrelizumab in Multiple Sclerosis: a Systematic Review
by: John L. Petrie, et al.
Published: (2024-10-01)

Role of Ocrelizumab in modulating gene and microRNA expression in multiple sclerosis
by: Bruna De Felice, et al.
Published: (2025-08-01)

The Role of the New Anti-CD20 Monoclonal Antibodies in Active Relapsing – Remitting Multiple Sclerosis Treatment: Efficacy and Safety of ofatumumab
by: I. Jonušaitė, et al.
Published: (2024-03-01)

The effectiveness and safety of ofatumumab for the treatment of pemphigus vulgaris: a cohort study based on a registry database
by: Xiwen Zhang, et al.
Published: (2025-07-01)

Persistence to Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis: Results from the German NeuroTransData Registry
by: Stefan Braune, et al.
Published: (2025-06-01)

Case Report: Neurofilament light chain in the follow up of progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with ocrelizumab
by: Raquel Piñar-Morales, et al.
Published: (2025-04-01)

Corrigendum: Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
by: Fernando Rodríguez-Jorge, et al.
Published: (2024-12-01)

Clinical Features of Patients with COVID-19 Recurrence During Hospitalization in the Omicron Variant Surge
by: Seki M, et al.
Published: (2024-11-01)

Case Report: Severe psoriasis skin lesions following ofatumumab treatment for multiple sclerosis
by: Wioletta Katarzyna Żukowicz-Wyrwa, et al.
Published: (2025-08-01)

Using major histocompatibility complex (MHC) II expression to predict antitumor response to CD4 + lymphocyte depletion
by: Yanping Wang, et al.
Published: (2025-02-01)

Case report: The case report of ofatumumab, a fully human anti-CD20 monoclonal antibody, in the treatment of KLHL11 encephalitis
by: Min Deng, et al.
Published: (2024-11-01)

B-Cell-Depleting Immune Therapies as Potential New Treatment Options for Systemic Sclerosis
by: Gerhard Zugmaier, et al.
Published: (2025-01-01)

Persistent SARS-CoV-2 infection resolved after B-cell recovery in a patient with follicular lymphoma treated with B-cell depletion therapy
by: Yuriko Sueda, et al.
Published: (2024-01-01)

Induction of cell death in malignant cells and regulatory T cells in the tumor microenvironment by targeting CD137
by: Rui Sun, et al.
Published: (2025-12-01)

Profile of Ofatumumab in the Treatment of Multiple Sclerosis: Design, Development and Place in Therapy
by: Awada Z, et al.
Published: (2024-12-01)

Case Report: Ofatumumab treatment for concomitant multiple sclerosis and idiopathic thrombocytopenic purpura
by: Yuki Yokota, et al.
Published: (2025-03-01)

Multiparameter flow cytometric and transcriptional analyis of CD20 positive T-cells in bone marrow in patients of multiple myeloma and monoclonal gammopathy of undetermined significance
by: Barbara Forró, et al.
Published: (2025-02-01)

Neuronal TDP-43 aggregation drives changes in microglial morphology prior to immunophenotype in amyotrophic lateral sclerosis
by: Molly E. V. Swanson, et al.
Published: (2025-02-01)

Clinical and analytical monitoring of patients with multiple sclerosis on anti-CD20 therapeutics: a real-world safety profile study
by: André Aires Fernandes, et al.
Published: (2025-01-01)

Hodgkin lymphoma: A clinicopathological and immunophenotypic study
by: Kaumudi Konkay, et al.
Published: (2016-01-01)

Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells
by: Federica Galota, et al.
Published: (2025-04-01)

A role of CD20+ T cells in early multiple sclerosis
by: Marina Rode von Essen, et al.
Published: (2025-05-01)

COVID-19 Vaccination Response in Patients with Multiple Sclerosis Treated with Ofatumumab in the United States: A Medical Record Review
by: Rahul H. Dave, et al.
Published: (2024-10-01)

Comparison of efficacy and adverse effects of CD19/20 CART versus CD19 single-target CART in R/R DLBCL: a single-center retrospective study
by: Bin Xue, et al.
Published: (2025-05-01)

CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma
by: Dan Zhu, et al.
Published: (2024-12-01)

Neolymphogenesis and Immunogistogochemical Study of Lymph Nodes in Breast Cancer
by: Sh. Kh. Gantsev, et al.
Published: (2020-01-01)

Quantitative analysis of tumor-infiltrating lymphocytes in meningiomas of the brain
by: S. I. Tertishniy, et al.
Published: (2016-08-01)

Loss of CD20 Expression in Follicular Lymphoma after Program Anti-Tumor Therapy Including Rituximab: Literature Data and Case Report
by: OM Volodina, et al.
Published: (2017-04-01)

Venetoclax-Based Regimens in CLL: Immunoglobulin G Levels, Absolute Neutrophil Counts, and Infectious Complications
by: Wojciech Szlasa, et al.
Published: (2025-06-01)